Vaccines based on replication incompetent Ad26 viral vectors: Standardized template with key considerations for a risk/benefit assessment-Reference-Cited by-同舟云学术

Vaccines based on replication incompetent Ad26 viral vectors: Standardized template with key considerations for a risk/benefit assessment

Published:2021-05 Issue:22 Volume:39 Page:3081-3101
ISSN:0264-410X
Container-title:Vaccine
language:en
Short-container-title:Vaccine

Author:

Custers Jerome,Kim Denny,Leyssen Maarten,Gurwith Marc,Tomaka Frank,Robertson James,Heijnen Esther,Condit Richard,Shukarev Georgi,Heerwegh Dirk,van Heesbeen Roy,Schuitemaker Hanneke,Douoguih Macaya,Evans Eric,Smith Emily R.,Chen Robert T.

Funder

World Health Organization

Publisher

Elsevier BV

Subject

Infectious Diseases,Public Health, Environmental and Occupational Health,General Veterinary,General Immunology and Microbiology,Molecular Medicine

Reference75 articles.

1. rVSVΔG-ZEBOV-GP (also designated V920) recombinant vesicular stomatitis virus pseudotyped with Ebola Zaire glycoprotein: standardized template with key considerations for a risk/benefit assessment;Monath;Vaccine X,2019

2. Four newly recognized adenoviruses;Rosen;Proc Soc Exp Biol Med,1961

3. Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: efficient human cell infection and bypass of preexisting adenovirus immunity;Vogels;J Virol,2003

4. Safety and immunogenicity of a replication-incompetent adenovirus type 5 HIV-1 clade B gag/pol/nef vaccine in healthy adults;Priddy;Clin Infect Dis,2008

5. HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis;McElrath;Lancet,2008

Cited by 59 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Recent Advances in Therapeutic Approaches Against Ebola Virus Infection;Recent Advances in Anti-Infective Drug Discovery;2024-11

2. Mucosal adenovirus vaccine boosting elicits IgA and durably prevents XBB.1.16 infection in nonhuman primates;Nature Immunology;2024-09-03

3. Long-term efficacy and immunogenicity of Ad26.RSV.preF–RSV preF protein vaccine (CYPRESS): a randomised, double-blind, placebo-controlled, phase 2b study;The Lancet Infectious Diseases;2024-09

4. Development of a novel adenovirus serotype 35 vector vaccine possessing an RGD peptide in the fiber knob and the E4 orf 4, 6, and 6/7 regions of adenovirus serotype 5;International Journal of Pharmaceutics;2024-09

5. Viral vector- and virus-like particle-based vaccines against infectious diseases: A minireview;Heliyon;2024-08